AG490 inhibited STAT3 activation and exhibited anti-cancer effects such as inhibition of cell growth and induction of apoptosis via targeting of JAK2 in preclinical models of breast cancer[4], gastric cancer[48], pancreatic cancer[144], and gallbladder cancer[145], among others. Here, STAT3 is linked to gastric cancer.